A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer

Abstract Background Trifluridine/Tipiracil (TAS-102) is an effective agent for the late-line treatment of metastatic colorectal cancer (mCRC). Combining TAS-102 with bevacizumab improves outcomes but may increase adverse events. We conducted a real-world, retrospective, exploratory comparison of two...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shaocheng Zeng, Huangying Deng, Hanzhi Dong, Chunye Huang, Ruiwen Ruan, Xiaofeng Dai, Jianping Xiong, Jun Deng, Yangyang Yao
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2026-02-01
coleção:	Discover Oncology
Assuntos:	Trifluridine/Tipiracil Bevacizumab Metastatic colorectal cancer Prognostic analysis
Acesso em linha:	https://doi.org/10.1007/s12672-026-04459-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!